Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Share News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 13.75
Bid: 13.50
Ask: 14.00
Change: 0.00 (0.00%)
Spread: 0.50 (3.704%)
Open: 13.75
High: 13.75
Low: 13.75
Prev. Close: 13.75
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

ANGLE sells Geomerics business to ARM Holdings

Fri, 13th Dec 2013 11:41

Specialist medtech company ANGLE has raised 6.2m pounds after realising its investment in graphics technology developer Geomerics, which it sold to ARM Holdings. The group said the additional financial resources will be used within its Parsortix non-invasive cancer diagnostics business, enabling it to deliver commercial returns during the next few years. The transaction is expected to contribute up to £1.5m to the company's 2014 financial year profit. £5.5m will be received immediately, while the remaining £0.7m will be paid on December 12th 2015. Andrew Newland, Chief Executive, said: "We are delighted by this transaction and believe that ARM, one the UK's most successful technology companies, represents the ideal custodian for Geomerics' technology and workforce. "The realisation of our shareholding in Geomerics is a key step in strengthening ANGLE's ability to deliver significant shareholder returns from the deployment of our Parsortix platform in the multi-billion dollar clinical market for the diagnosis and treatment of cancer." NR
More News
22 Oct 2020 16:01

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
20 Oct 2020 14:18

IN BRIEF: Angle Says FDA Accepts Parsotix Submission For Breast Cancer

IN BRIEF: Angle Says FDA Accepts Parsotix Submission For Breast Cancer

Read more
20 Oct 2020 08:58

FDA accepts Angle's review submission for Parsortix PC1

(Sharecast News) - Liquid biopsy company Angle announced on Tuesday that the US Food and Drug Administration (FDA) has completed its administrative review, and accepted the company's submission for substantive review.

Read more
28 Sep 2020 19:33

IN BRIEF: Angle Submits US FDA De Novo Application For Parsortix

IN BRIEF: Angle Submits US FDA De Novo Application For Parsortix

Read more
20 Aug 2020 16:00

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
14 Aug 2020 12:41

Angle's Parsortix Able To Predict Patients' Response To Treatment

Angle's Parsortix Able To Predict Patients' Response To Treatment

Read more
20 Jul 2020 20:03

IN BRIEF: Angle Notes Study Showing "Key Capabilities" Of Parsortix

IN BRIEF: Angle Notes Study Showing "Key Capabilities" Of Parsortix

Read more
20 Jul 2020 10:16

Angle's 'Parsortix' advantageous in breast cancer in new research

(Sharecast News) - Angle announced on Monday that the University of Southern California (USC) has published peer-reviewed results of new work undertaken in metastatic breast cancer (MBC), highlighting advantages of a 'Parsortix' liquid biopsy, compared to standard-of-care tissue biopsy.

Read more
25 Jun 2020 12:22

Angle Progresses On Parsortix And De Novo Clearance From US Regulator

Angle Progresses On Parsortix And De Novo Clearance From US Regulator

Read more
18 Jun 2020 16:05

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
10 Jun 2020 16:41

IN BRIEF: Haydale Graphene Appoints Former AIM Market COO To Board

IN BRIEF: Haydale Graphene Appoints Former AIM Market COO To Board

Read more
12 May 2020 18:54

Angle's Parsortix Could Be Used To Pick MET Inhibitor Trial Subjects

Angle's Parsortix Could Be Used To Pick MET Inhibitor Trial Subjects

Read more
12 May 2020 08:58

Angle upbeat on recent research using 'Parsortix'

(Sharecast News) - Liquid biopsy company Angle announced on Tuesday that the liquid biopsy analysis unit at the Health Research Institute of Santiago in Spain has published results of new work undertaken in head and neck cancer and non small cell lung cancer, on the potential utility of a liquid biopsy-based strategy to assess MET alterations on circulating tumour cells (CTCs).

Read more
28 Apr 2020 12:28

UK TRADING UPDATE SUMMARY: Zenith Latest To Join Global Drive For PPE

UK TRADING UPDATE SUMMARY: Zenith Latest To Join Global Drive For PPE

Read more
28 Apr 2020 10:03

Angle works with skeleton R&D crew during lockdown

(Sharecast News) - Biopharmaceuticals group Angle said on Tuesday that progress had been impeded by the Covid-19 outbreak as the firm worked with a research and development skeleton crew in Guildford.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.